This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chau, N.-M. Articles by Ashcroft, M. Search for Related Content PubMed PubMed Citation Articles by Chau, N.-M. Articles by Ashcroft, M.

Identification of Novel Small Molecule Inhibitors of Hypoxia-Inducible Factor-1 That Differentially Block Hypoxia-Inducible Factor-1 Activity and Hypoxia-Inducible Factor-1 Induction in Response to Hypoxic Stress and Growth Factors

¹ Cell Growth Regulation and Angiogenesis Team, ² Analytical Technology and Screening Team, ³ Medicinal Chemistry Department, and ⁴ Signal Transduction and Molecular Pharmacology Team, Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, United Kingdom

Requests for reprints: Margaret Ashcroft, Cell Growth Regulation and Angiogenesis Team, Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom. Phone: 44-208-722-4035; Fax: 44-208-722-4205; E-mail: margaret.ashcroft{at}icr.ac.uk.

Hypoxia-inducible factor-1 (HIF-1) is a transcriptional complex that is activated in response to hypoxia and growth factors. HIF-1 plays a central role in tumor progression, invasion, and metastasis. Overexpression of the HIF-1 subunit has been observed in many human cancers and is associated with a poor prognostic outcome with conventional treatments. Targeting HIF-1 using novel small molecule inhibitors is, therefore, an attractive strategy for therapeutic development. We have generated U2OS human osteosarcoma cells stably expressing a luciferase reporter construct under the control of a hypoxia response element (U2OS-HRE-luc). The U2OS-HRE-luc cells were robustly and reproducibly sensitive to hypoxic stress in a HIF-1–dependent manner. We developed an automated U2OS-HRE-luc cell-based assay that was used in a high-throughput screen to identify compounds that inhibited HIF-1 activity induced by treatment with the hypoxia mimetic, deferoxamine mesylate. We performed a pilot screen of the National Cancer Institute Diversity Set of 2,000 compounds. We identified eight hit compounds, six of these were also identified by Rapisarda et al. in an independent hypoxia screen. However, there were two novel hit compounds, NSC-134754 and NSC-643735, that did not significantly inhibit constitutive luciferase activity in U2OS cells (U2OS-luc). We showed that both NSC-134754 and NSC-643735 significantly inhibited HIF-1 activity and HIF-1 protein induced by deferoxamine mesylate. Interestingly, NSC-134754 but not NCS-643735 inhibited HIF-1 activity and HIF-1 protein induced by hypoxia and significantly inhibited Glut-1 expression. Finally, we showed that both NCS-134754 and NCS-643735 inhibited HIF-1 protein induced by insulin-like growth factor-1. Our cell-based assay approach has successfully identified novel compounds that differentially target hypoxia and/or growth factor–mediated induction of HIF-1.

This article has been cited by other articles:

				C. Wan, S. R. Gilbert, Y. Wang, X. Cao, X. Shen, G. Ramaswamy, K. A. Jacobsen, Z. S. Alaql, A. W. Eberhardt, L. C. Gerstenfeld, et al. Activation of the hypoxia-inducible factor-1{alpha} pathway accelerates bone regeneration PNAS, January 15, 2008; 105(2): 686 - 691. [Abstract] [Full Text] [PDF]

				X. Lin, C. A. David, J. B. Donnelly, M. Michaelides, N. S. Chandel, X. Huang, U. Warrior, F. Weinberg, K. V. Tormos, S. W. Fesik, et al. A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation PNAS, January 8, 2008; 105(1): 174 - 179. [Abstract] [Full Text] [PDF]

				P. D. Sutphin, D. A. Chan, J. M. Li, S. Turcotte, A. J. Krieg, and A. J. Giaccia Targeting the Loss of the von Hippel-Lindau Tumor Suppressor Gene in Renal Cell Carcinoma Cells Cancer Res., June 15, 2007; 67(12): 5896 - 5905. [Abstract] [Full Text] [PDF]

				D. P. Schuster, S. L. Brody, Z. Zhou, M. Bernstein, R. Arch, D. Link, and M. Mueckler Regulation of lipopolysaccharide-induced increases in neutrophil glucose uptake Am J Physiol Lung Cell Mol Physiol, April 1, 2007; 292(4): L845 - L851. [Abstract] [Full Text] [PDF]

				K S Kimbro and J W Simons Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 739 - 749. [Abstract] [Full Text] [PDF]

				G. M. Woldemichael, J. R. Vasselli, R. S. Gardella, T. C. Mckee, W. M. Linehan, and J. B. McMahon Development of a Cell-Based Reporter Assay for Screening of Inhibitors of Hypoxia-Inducible Factor 2-Induced Gene Expression J Biomol Screen, September 1, 2006; 11(6): 678 - 687. [Abstract] [PDF]

				D. T. Jones and A. L. Harris Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. Mol. Cancer Ther., September 1, 2006; 5(9): 2193 - 2202. [Abstract] [Full Text] [PDF]

				D. Hussein, E. J. Estlin, C. Dive, and G. W.J. Makin Chronic hypoxia promotes hypoxia-inducible factor-1{alpha}-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol. Cancer Ther., September 1, 2006; 5(9): 2241 - 2250. [Abstract] [Full Text] [PDF]

				V. A. Carroll and M. Ashcroft Role of Hypoxia-Inducible Factor (HIF)-1{alpha} versus HIF-2{alpha} in the Regulation of HIF Target Genes in Response to Hypoxia, Insulin-Like Growth Factor-I, or Loss of von Hippel-Lindau Function: Implications for Targeting the HIF Pathway. Cancer Res., June 15, 2006; 66(12): 6264 - 6270. [Abstract] [Full Text] [PDF]